Protalix BioTherapeutics (PLX) Shares Outstanding (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Shares Outstanding (Entity) of $80.6 million for Q1 2026, up 1.21% year-over-year from $79.6 million in Q1 2025, and little changed quarter-over-quarter from $80.4 million in Q4 2025.
Protalix BioTherapeutics (PLX) Shares Outstanding (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Shares Outstanding (Entity) history runs 17 years deep, the most recent figure standing at $80.6 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 1.21% year-over-year to $80.6 million; the TTM figure through Mar 2026 stood at $80.6 million (up 1.21% YoY), while the FY2025 annual figure was $80.4 million, up 6.03% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $80.6 million, roughly flat from $80.4 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $80.6 million in Q1 2026, with the low at $46.3 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $73.1 million (2024), against an average of $69.1 million.
- The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Entity) soared 46.94% in 2023, then climbed 0.93% in 2024.
- Protalix BioTherapeutics' Shares Outstanding (Entity) stood at $53.8 million in 2022, then jumped by 35.62% to $73.0 million in 2023, then grew by 3.97% to $75.9 million in 2024, then rose by 6.03% to $80.4 million in 2025, then climbed by 0.18% to $80.6 million in 2026.
- Business Quant data shows PLX's Shares Outstanding (Entity) at $80.6 million in Q1 2026, $80.4 million in Q4 2025, and $80.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | 79.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 79.85 Mn |
| Mar 31, 2026 | 79.85 Mn |
| Dec 31, 2025 | 78.55 Mn |
| Sep 30, 2025 | 79.28 Mn |
| Jun 30, 2025 | 78.66 Mn |
| Mar 31, 2025 | 76.61 Mn |
| Dec 31, 2024 | 72.53 Mn |
| Sep 30, 2024 | 73.55 Mn |
| Jun 30, 2024 | 73.31 Mn |
| Mar 31, 2024 | 73.04 Mn |
| Dec 31, 2023 | 67.51 Mn |
| Sep 30, 2023 | 72.28 Mn |
| Jun 30, 2023 | 67.16 Mn |
| Mar 31, 2023 | 57.48 Mn |
| Dec 31, 2022 | 48.47 Mn |
| Sep 30, 2022 | 49.50 Mn |
| Jun 30, 2022 | 47.33 Mn |
| Mar 31, 2022 | 45.84 Mn |
| Dec 31, 2021 | 44.14 Mn |
| Sep 30, 2021 | 45.56 Mn |